DEF 14A: Aspira Women's Health Seeks Stockholder Approval for Director Elections, Executive Pay, and Stock Incentive Plan Amendment

Aspira Women's Health is holding its annual meeting on May 13, 2024, to vote on director elections, executive compensation, an amendment to the stock incentive plan, and ratification of the independent accounting firm.

Summary

• Aspira Women's Health Inc. will hold its 2024 Annual Meeting of Stockholders on May 13, 2024, virtually.
• Stockholders will vote on the election of six directors, an advisory vote on executive compensation, an amendment to the 2019 Stock Incentive Plan, and the ratification of BDO USA, LLP as the independent registered public accounting firm for the year ending December 31, 2024.
• The Board of Directors recommends voting for all proposals.
• The record date for determining stockholders eligible to vote is March 18, 2024.
• The company is soliciting proxies for the meeting and will bear the related costs.
• The proxy statement and the company's Annual Report on Form 10-K for the year ended December 31, 2023, are available online.
• The company is requesting approval for an amendment to the Aspira Womens Health Inc. 2019 Stock Incentive Plan (the 2019 Plan) to effectuate an increase in the number of shares of common stock of the Company authorized to be granted under the 2019 Plan by 1,000,000 shares so that a total of 2,032,818 shares of common stock are authorized to be granted under the 2019 Plan.
• Stockholder approval is being sought to increase the aggregate maximum number of shares of our common stock that may be issued under the 2019 Plan pursuant to the exercise of incentive stock options to a maximum of 3,000,000 shares that may be issued pursuant to the exercise of incentive stock options under the 2019 Plan.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda for the annual meeting and seeking stockholder approval for various proposals. The sentiment is neutral to slightly positive, as the company is taking steps to ensure good governance and align management's interests with those of shareholders.

Positives

• The proposed amendment to the 2019 Stock Incentive Plan aims to attract, retain, motivate, and reward participants, aligning their interests with those of stockholders.
• The company has implemented corporate governance best practices, including an independent board committee administering the 2019 Plan and prohibitions on repricing stock options without stockholder approval.
• The company has a clawback policy in place, allowing for the recovery of awards in the event of financial restatements or violations of restrictive covenants.

Risks

• If the proposed amendment to the 2019 Stock Incentive Plan is not approved, the company may face difficulties in recruiting, retaining, and motivating officers and employees.
• The company's ability to realize the benefit of any tax deductions depends on its generation of taxable income and compliance with tax reporting obligations.

Future Outlook

The company aims to continue providing appropriate incentives for sustaining financial and operating performance and leadership excellence through equity-based compensation awards.

Management Comments

• The Board believes that separation of the positions of the Chair and Chief Executive Officer reinforces the independence of the Board in its oversight of the business and affairs of the Company.
• The Board believes that granting equity-based compensation awards to our officers, employees, directors and consultants is an effective means to provide appropriate incentives for sustaining our financial and operating performance and leadership excellence, to align the interests of award recipients with those of our stockholders and to encourage them to remain with us for long and productive careers.

Industry Context

The document reflects standard corporate governance practices, including the election of directors, executive compensation, and the use of stock incentive plans to align management's interests with those of shareholders.

Comparison to Industry Standards

• The director compensation program is designed to attract qualified non-employee directors and to fairly compensate them for their substantial responsibilities and time commitment, which is a common practice among publicly traded companies.
• The company's approach to executive compensation, which includes base salaries, annual incentive bonuses, and equity incentive compensation, is consistent with industry standards.
• The company's clawback policy is in line with the Dodd-Frank Act requirements and reflects a commitment to corporate governance best practices.

Related Party Transactions

• In connection with a May 8, 2013 private placement, Oracle Partners, LP and Oracle Ten Fund Master LP, together, and Jack W. Schuler (the Principal Purchasers) received rights to prohibit the Company from taking any of the following actions unless agreed to by at least one of the Principal Purchasers: Making any acquisition with a value greater than $2 million; Entering into, or amending the terms of our agreements with Quest Diagnostics, which consent shall not be unreasonably withheld, conditioned or delayed following good faith consultation with the Company; Submitting any resolution at a meeting of stockholders or in any other manner changing or authorizing a change in the size of our Board; Offering, selling or issuing any securities senior to the Company’s common stock or any securities that are convertible into or exchangeable or exercisable for securities ranking senior to our common stock; Amending our Certificate of Incorporation or Bylaws in any manner that effects the rights, privileges or economics of the Company’s common stock; Making any action that would result in a change in control of the Company or an insolvency event; Paying or declaring dividends on any securities of the Company or distributing the assets of the Company other than in the ordinary course of business or repurchasing any outstanding securities of the Company; or Adopting or amending any shareholder rights plan.
• In addition, the Principal Purchasers each received the right to nominate a member to serve on our Board.
• In the underwritten public offering of our common stock that we completed on August 22, 2022, and certain of our directors and officers purchased an aggregate of 113,333 shares of our common stock (as adjusted for the reverse stock split) for aggregate gross proceeds of $170,000.00.
• Also, certain of our directors and officers participated in the underwritten public offering of our common stock that we completed on July 24, 2023, and purchased an aggregate of 44,347 shares of our common stock for aggregate gross proceeds of $176,501.06.
• Further, certain of our directors and officers participated in the underwritten public offering of our common stock that we completed on January 26, 2024, and purchased an aggregate of 2,400 shares of our common stock for aggregate gross proceeds of $10,212.

Stakeholder Impact

• Approval of the stock incentive plan amendment could positively impact employees and executives by providing them with equity-based compensation.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.
• The election of directors will determine the leadership and oversight of the company, impacting all stakeholders.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will file the final voting results in a current report on Form 8-K within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Stock Incentive Plan, Director Elections, BDO USA, LLP, Corporate Governance, Aspira Womens Health